Health

Results: 25-36 of 5938

ACCESS Newswire associated0

AGFA HealthCare Achieves HITRUST I1 Certification, Demonstrating Its Commitment to and Compliance With Data Protection Standards, and Protecting Against Cybersecurity Threats

4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing

SciBase Launches Nevisense Pilot at Leading University in Southeast Florida

PR Newswire associated0

GORE ANNOUNCES MDR EXPANDED INDICATION FOR THE GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS AS A BRIDGING STENT

PR Newswire associated0

First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Technimark Unveils New Brand Identity: "We Make What Makes Life Better"

PR Newswire associated0

Q'Apel Medical Announces U.S. FDA Clearance for the Zebra Neurovascular Access System and Prepares for Full U.S. Launch

ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025

ACCESS Newswire logo

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

Business Wire logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

Beacon Therapeutics completes enrollment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP